메뉴 건너뛰기




Volumn 20, Issue 119, 2011, Pages 201-205

A long-acting beta-2 agonist, no advantages in COPD
[No Author Info available]

Author keywords

[No Author keywords available]

Indexed keywords

BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CORTICOSTEROID; CYTOCHROME P450 3A4; CYTOCHROME P450 INHIBITOR; FORMOTEROL; FORMOTEROL FUMARATE; GLYCOPROTEIN P INHIBITOR; HYPERGLYCEMIC AGENT; INDACATEROL; PLACEBO; SALMETEROL; TIOTROPIUM BROMIDE; TOBACCO SMOKE; 5 (2 (5,6 DIETHYLINDAN 2 YLAMINO) 1 HYDROXYETHYL) 8 HYDROXY 1H QUINOLIN 2 ONE; 5-(2-(5,6-DIETHYLINDAN-2-YLAMINO)-1-HYDROXYETHYL)-8-HYDROXY-1H-QUINOLIN-2-ONE; BETA 2 ADRENERGIC RECEPTOR STIMULATING AGENT; BRONCHODILATING AGENT; INDAN DERIVATIVE; QUINOLONE DERIVATIVE;

EID: 80052205244     PISSN: 11677422     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Short Survey
Times cited : (1)

References (12)
  • 1
    • 78049407036 scopus 로고    scopus 로고
    • Chronic obstructive pulmonary disease: Stopping smoking slows disease progression
    • Prescrire Editorial Staff
    • Prescrire Editorial Staff"Chronic obstructive pulmonary disease: stopping smoking slows disease progression" Prescrire Int 2004; 13 (71): 111.
    • (2004) Prescrire Int , vol.13 , Issue.71 , pp. 111
  • 2
    • 4644253835 scopus 로고    scopus 로고
    • Chronic obstructive pulmonary disease
    • The Pharmaceutical Press, London. accessed 26 November 2010
    • "Chronic obstructive pulmonary disease". In: "Martindale The Complete Drug Reference"The Pharmaceutical Press, London. www.medicinescomplete.com accessed 26 November 2010: 12 pages.
    • Martindale the Complete Drug Reference , pp. 12
  • 4
    • 79953026850 scopus 로고    scopus 로고
    • Once-daily indacaterol versus twice-daily salmeterol for COPD: A placebo-controlled comparison
    • Kornmann O. et al. "Once-daily indacaterol versus twice-daily salmeterol for COPD: a placebo-controlled comparison" Eur Respir J 2011; 37: 273-279.
    • (2011) Eur Respir J , vol.37 , pp. 273-279
    • Kornmann, O.1
  • 6
    • 77953707790 scopus 로고    scopus 로고
    • Efficacity of a new once-daily longacting inhaled beta2-agonist indacatérol versus twice-daily formoterol in COPD
    • Dahl R. et al. "Efficacity of a new once-daily longacting inhaled beta2-agonist indacatérol versus twice-daily formoterol in COPD" Thorax 2010; 65 (6): 473-479.
    • (2010) Thorax , vol.65 , Issue.6 , pp. 473-479
    • Dahl, R.1
  • 8
    • 77951221549 scopus 로고    scopus 로고
    • Efficacy and safety of indacaterol 150 microg once-daily in COPD: A doubleblind, randomised, 12-week study
    • Feldman G. et al. "Efficacy and safety of indacaterol 150 microg once-daily in COPD: a doubleblind, randomised, 12-week study" BMC Pulm Med 2010; 10: 9 pages.
    • (2010) BMC Pulm Med , vol.10 , pp. 9
    • Feldman, G.1
  • 9
    • 84910091829 scopus 로고    scopus 로고
    • Australian Government - Department of Health and Ageing - TGA October
    • Australian Government - Department of Health and Ageing - TGA "Australian public assessment report for indacaterol" October 2010: 106 pages.
    • (2010) Australian Public Assessment Report for Indacaterol , pp. 106
  • 10
    • 84857110207 scopus 로고    scopus 로고
    • 18-1 Patients asthmatiques ou bronchitiques chroniques
    • Prescrire Rédaction interactions médicamenteuses
    • Prescrire Rédaction "18-1 Patients asthmatiques ou bronchitiques chroniques" Rev Prescrire 2010; 30 (326 suppl. interactions médicamenteuses).
    • (2010) Rev Prescrire , vol.30 , Issue.326 SUPPL.
  • 12
    • 79751506102 scopus 로고    scopus 로고
    • Blinded 12-week comparison of once-daily indacaterol and tiotropium in COPD
    • Dunn L.J. et al. "Blinded 12-week comparison of once-daily indacaterol and tiotropium in COPD"Chest 2010; 138: 719A.
    • (2010) Chest , vol.138
    • Dunn, L.J.1


* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.